Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19822506 | 1.00 | XPO1 (0.40) | XPO1KEAP1NFE2L2TRPA1CYP2E1 | |
| SCHEMBL21048436 | 0.83 | XPO1 (0.52) | XPO1KEAP1NFE2L2TRPA1CYP2E1 | |
| SCHEMBL19822504 | 0.83 | XPO1 (0.52) | XPO1KEAP1NFE2L2TRPA1CYP2E1 | |
| SCHEMBL19822514 | 0.78 | XPO1 (0.34) | XPO1 | |
| SCHEMBL21048406 | 0.76 | NAAA (0.36) | XPO1HIF1ANAAA | |
| SCHEMBL21048405 | 0.76 | XPO1 (0.48) | XPO1KEAP1NFE2L2TRPA1CYP2E1 | |
| SCHEMBL19822524 | 0.76 | XPO1 (0.48) | XPO1KEAP1NFE2L2TRPA1CYP2E1 | |
| SCHEMBL21048404 | 0.75 | XPO1 (0.40) | XPO1TRPA1CYP2E1CYP2A6MIF | |
| SCHEMBL19822516 | 0.75 | XPO1 (0.40) | XPO1TRPA1CYP2E1CYP2A6MIF | |
| SCHEMBL21048407 | 0.75 | XPO1 (0.44) | XPO1MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10315990-B2 | Isothiocyanate compounds and isothiocyanate XPO1 protein inhibitor drugs thereof | DRIVINGFORCE THERAPEUTICS (CN) | 2019-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10315990-B2 | Isothiocyanate compounds and isothiocyanate XPO1 protein inhibitor drugs thereof | XPO1, XPOT, XPO4 | XPO1 1/4885KEAP1 10/4885NFE2L2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.